Featured Research

from universities, journals, and other organizations

Gliomas Exploit Immune Cells Of The Brain For Rapid Expansion

Date:
July 20, 2009
Source:
Helmholtz Association of German Research Centres
Summary:
Gliomas are among the most common and most malignant brain tumors. These tumors infiltrate normal brain tissue and grow very rapidly. As a result, surgery can never completely remove the tumor. Now, neurosurgeons and brain researchers have been able to show that glioma cells exploit microglia, the immune cells of the brain, for their expansion.

Gliomas are among the most common and most malignant brain tumors. These tumors infiltrate normal brain tissue and grow very rapidly. As a result, surgery can never completely remove the tumor.

Now, the neurosurgeons Dr. Darko S. Markovic (Helios Klinikum Berlin-Buch) and Dr. Michael Synowitz (Charitι) as well as Dr. Rainer Glass and Professor Helmut Kettenmann (both Max Delbrόck Center for Molecular Medicine, MDC, Berlin-Buch), have been able to show that glioma cells exploit microglia, the immune cells of the brain, for their expansion.

Microglial cells are the immune cells of the brain/central nervous system. They constantly screen the brain environment. On their surface they use sensors to detect changes in their environment due to brain damage or infections. An important family of these sensors are Toll-like receptors (TLR).

However, microglia do not attack glioma cells. On the contrary: they support the growth of the tumor and, thus, make the disease worse. Together with researchers in Warsaw, Poland, Amsterdam, The Netherlands, and Bethesda, USA, the researchers in Berlin have been able to show how the immune cells promote the tumor growth.

Microglial cells are attracted toward the glioma cells and gather in and around the tumor in large numbers. Interestingly, gliomas consist of up to 30 per cent of microglia, especially at the tumor edge.

Gliomas release certain enzymes, metalloproteases, which digest the extracellular matrix, and also dissolve the ties between cells. However, the metalloproteases are produced and released as inactive precursor protein which need to be cleaved to be activated. This cleavage is accomplished by another enzyme, which is produced by the microglial cells.

This enzyme is anchored in the membrane and was therefore named membrane type 1 metalloprotease (MT1-MMP). MT1-MMP activates the metalloproteases which clear the way for the glioma cells and allows them to infiltrate normal brain tissue and expand very rapidly.

Normally, microglial cells do not produce MT1-MMP. However, the glioma cells manipulate the microglial cells by stimulating microglial TLR which trigger the expression of MT1-MMP.

The researchers could confirm their data from petri dish in mice. "Those mice, in which we had knocked out the MT1-MMP gene or a crucial gene for TLR signalling, did attract fewer microglial cells and the tumor grew much more slowly", explains Professor Kettenmann.

They could also demonstrate that MT1-MMP was present in tissue from glioma patients. Remarkably, the gliomas with high level of microglial MT1-MMP were also more aggressive. Moreover microglial cells were more abundant in tissue sample from the tumor edge as compared to the center of the tumor.

Glioma cells themselves do not produce MT1-MMP. However, when the researchers experimentally over expressed MT1-MMP in glioma cells, they died.

The researchers hope, that interfering with TLR receptors or their intracellular pathways might reduce the rapid expansion of glioma cells. Professor Kettenmann: "Microglia are a new target for glioma researchers."


Story Source:

The above story is based on materials provided by Helmholtz Association of German Research Centres. Note: Materials may be edited for content and length.


Journal Reference:

  1. D. S. Markovica, K. Vinnakotaa, S. Chirasania, M. Synowitza, H. Ragueta, K. Stocka, M. Sliwad, S. Lehmanne, R. Ka¨ linf,N. van Rooijeng, K. Holmbeckh, F. L. Heppnerf, J. Kiwitb, V. Matyasha, S. Lehnardte, B. Kaminskad, R. Glassa, and H. Kettenmanna,. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proceedings of the National Academy of Sciences, 2009; DOI: 10.1073/pnas.0804273106

Cite This Page:

Helmholtz Association of German Research Centres. "Gliomas Exploit Immune Cells Of The Brain For Rapid Expansion." ScienceDaily. ScienceDaily, 20 July 2009. <www.sciencedaily.com/releases/2009/07/090716113250.htm>.
Helmholtz Association of German Research Centres. (2009, July 20). Gliomas Exploit Immune Cells Of The Brain For Rapid Expansion. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/07/090716113250.htm
Helmholtz Association of German Research Centres. "Gliomas Exploit Immune Cells Of The Brain For Rapid Expansion." ScienceDaily. www.sciencedaily.com/releases/2009/07/090716113250.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins